

HB 4102-1  
(LC 59)  
2/4/20 (LHF/ps)

Requested by Representative PRUSAK

**PROPOSED AMENDMENTS TO  
HOUSE BILL 4102**

1 On page 1 of the printed bill, line 14, after “to” delete the rest of the line  
2 and delete line 15 and insert “an appeal.”.

3 On page 4, line 29, after “or” delete the rest of the line and insert “failure  
4 to provide additional clinical information requested by the insurer;”.

5 On page 7, line 5, delete the period and delete lines 6 through 9 and insert  
6 “, unless otherwise provided by federal law.

7 “(k) If a change in a drug formulary or other change in coverage impacts  
8 the coverage of an enrollee’s treatment plan and the enrollee has been sta-  
9 bilized on the treatment plan for at least 90 days, the insurer must continue  
10 to provide coverage of the treatment until utilization review and all internal  
11 appeals and external reviews are completed.”.

12 On page 9, line 9, delete “an interchangeable biological”.

13 In line 10, delete “product” and insert “a biosimilar agent approved by the  
14 United States Food and Drug Administration”.

15 On page 14, after line 18, insert:

16 **“SECTION 11. (1) As used in this section, ‘health benefit plan’ has  
17 the meaning given that term in ORS 743B.005.**

18 **“(2) ORS 743B.423 (2)(d)(B), (k) and (n) does not apply to health  
19 benefit plans offered to public employees by the Public Employees’  
20 Benefit Board.**

21 **“(3) ORS 743B.602 (2)(c) does not apply to health benefit plans of-**

1 **ferred to public employees by the Public Employees' Benefit Board or**  
2 **the Oregon Educators Benefit Board.”.**

3 \_\_\_\_\_